These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1979366)

  • 1. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon.
    Bunker CB; Terenghi G; Springall DR; Polak JM; Dowd PM
    Lancet; 1990 Dec 22-29; 336(8730):1530-3. PubMed ID: 1979366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis.
    Terenghi G; Bunker CB; Liu YF; Springall DR; Cowen T; Dowd PM; Polak JM
    J Pathol; 1991 Jul; 164(3):245-52. PubMed ID: 1832448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon.
    Bunker CB; Reavley C; O'Shaughnessy DJ; Dowd PM
    Lancet; 1993 Jul; 342(8863):80-3. PubMed ID: 8100913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease.
    Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD
    Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis.
    Knock GA; Terenghi G; Bunker CB; Bull HA; Dowd PM; Polak JM
    J Invest Dermatol; 1993 Jul; 101(1):73-8. PubMed ID: 8331298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digital cutaneous vascular responses to histamine and neuropeptides in Raynaud's phenomenon.
    Bunker CB; Foreman JC; Dowd PM
    J Invest Dermatol; 1991 Mar; 96(3):314-7. PubMed ID: 2002251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon.
    Istok R; Czirják L; Lukác J; Stancíková M; Rovenský J
    Rheumatology (Oxford); 2001 Feb; 40(2):140-6. PubMed ID: 11257149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective suprasensitivity to calcitonin-gene-related peptide in the hands in Raynaud's phenomenon.
    Shawket S; Dickerson C; Hazleman B; Brown MJ
    Lancet; 1989 Dec; 2(8676):1354-7. PubMed ID: 2574303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artifactual hypoglycaemia in a patient with scleroderma and Raynaud's phenomenon.
    Osman R; Erasmus E; Lahri S; Moosajee F
    S Afr Med J; 2021 Feb; 111(2):13202. PubMed ID: 33944714
    [No Abstract]   [Full Text] [Related]  

  • 19. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raynaud's phenomenon and vascular disease in scleroderma.
    Kahaleh MB
    Curr Opin Rheumatol; 1994 Nov; 6(6):621-7. PubMed ID: 7865384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.